AU2017250732B2 - Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative - Google Patents

Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative Download PDF

Info

Publication number
AU2017250732B2
AU2017250732B2 AU2017250732A AU2017250732A AU2017250732B2 AU 2017250732 B2 AU2017250732 B2 AU 2017250732B2 AU 2017250732 A AU2017250732 A AU 2017250732A AU 2017250732 A AU2017250732 A AU 2017250732A AU 2017250732 B2 AU2017250732 B2 AU 2017250732B2
Authority
AU
Australia
Prior art keywords
bchl
treatment
vtp
pdt
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017250732A
Other languages
English (en)
Other versions
AU2017250732A1 (en
Inventor
Lilach Agemy
Jonathan Coleman
Rachel HAMRI
Kwanghee Kim
Dina PREISE
Yoram Salomon
Avigdor Scherz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Memorial Sloan Kettering Cancer Center filed Critical Yeda Research and Development Co Ltd
Publication of AU2017250732A1 publication Critical patent/AU2017250732A1/en
Application granted granted Critical
Publication of AU2017250732B2 publication Critical patent/AU2017250732B2/en
Priority to AU2023200591A priority Critical patent/AU2023200591A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017250732A 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative Active AU2017250732B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200591A AU2023200591A1 (en) 2016-04-10 2023-02-06 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200591A Division AU2023200591A1 (en) 2016-04-10 2023-02-06 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Publications (2)

Publication Number Publication Date
AU2017250732A1 AU2017250732A1 (en) 2018-11-15
AU2017250732B2 true AU2017250732B2 (en) 2022-11-10

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017250732A Active AU2017250732B2 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
AU2023200591A Abandoned AU2023200591A1 (en) 2016-04-10 2023-02-06 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200591A Abandoned AU2023200591A1 (en) 2016-04-10 2023-02-06 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Country Status (14)

Country Link
US (2) US11278555B2 (https=)
EP (1) EP3442582A1 (https=)
JP (2) JP2019510807A (https=)
KR (2) KR20190008206A (https=)
CN (2) CN118304400A (https=)
AU (2) AU2017250732B2 (https=)
BR (1) BR112018070847A2 (https=)
CA (1) CA3020067A1 (https=)
IL (1) IL262191B2 (https=)
MX (2) MX390751B (https=)
RU (2) RU2021110230A (https=)
SG (1) SG11201808849TA (https=)
WO (1) WO2017179053A1 (https=)
ZA (1) ZA201807187B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040232A1 (en) * 1999-12-01 2001-06-07 Yeda Research And Development Co. Ltd. Chlorophyll and bacteriochlorophyll esters, and their preparation
WO2004045492A2 (en) * 2002-11-17 2004-06-03 Yeda Research And Development Co. Ltd. Water-soluble anionic bacteriochlorophyll derivatives and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347554T1 (de) 1998-12-09 2006-12-15 Yeda Res & Dev Palladiumsubstituierte bakteriochlorophyllderivate und deren verwendung
PT2061512T (pt) 2006-08-23 2020-01-14 Yeda Res & Dev Conjugados de péptidos com rgd e fotossensibilizantes de (bacterio)clorofila e as suas utilizações
US8673270B2 (en) 2008-10-23 2014-03-18 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040232A1 (en) * 1999-12-01 2001-06-07 Yeda Research And Development Co. Ltd. Chlorophyll and bacteriochlorophyll esters, and their preparation
WO2004045492A2 (en) * 2002-11-17 2004-06-03 Yeda Research And Development Co. Ltd. Water-soluble anionic bacteriochlorophyll derivatives and their uses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EUN TAEK PARK, MOO IN PARK, SEUN JA PARK, SANG-WOO CHA, KYO-SANG YOO: "Su2031 Comparison Outcomes for Unresectable Hilar Cholangiocarcinoma Treated With Definitive Photodynamic Therapy(PDT)Combined With Gemcitabine-Based Chemotherapy and Conservative Treatment", GASTROENTEROLOGY, ELSEVIER INC., US, vol. 142, no. 5, 1 May 2012 (2012-05-01), US , pages S - 977, XP055387087, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(12)63788-3 *
GANG SUN, MARLYS A. ANDERSON, EMMANUEL C. GOROSPE, CADMAN L. LEGGETT, LORI S. LUTZKE, LOUIS M. WONG KEE SONG, MICHAEL LEVY, KENNET: "Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines", LASERS IN SURGERY AND MEDICINE., WILEY- LISS, NEW YORK., US, vol. 44, no. 9, 27 November 2012 (2012-11-27), US , pages 755 - 761, XP055386986, ISSN: 0196-8092, DOI: 10.1002/lsm.22073 *
MOORE C M ET AL., NATURE CLINICAL PRACTICE URO, NATURE PUBLISHING GROUP, LONDON, GB, (2009-01-01), vol. 6, no. 1, doi:10.1038/NCPURO1274, ISSN 1743-4270, pages 18 - 30 *
OHAD MAZOR ET AL., PHOTOCHEMISTRY AND PHOTOBIOLOGY, (2004-01-01), vol. 81, no. 2, doi:10.1562/2004-06-14-RA-199, ISSN 0031-8655, pages 342 - 51 *
YOSHIKAZU NONAKA, ATSUSHI NANASHIMA, TAKASHI NONAKA, MASATAKA UEHARA, HAJIME ISOMOTO, TAKAFUMI ABO, TAKESHI NAGAYASU: "Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA., US, vol. 181, no. 2, 1 May 2013 (2013-05-01), US , pages 234 - 241, XP055387041, ISSN: 0022-4804, DOI: 10.1016/j.jss.2012.06.047 *

Also Published As

Publication number Publication date
CA3020067A1 (en) 2017-10-19
US20220202838A1 (en) 2022-06-30
WO2017179053A1 (en) 2017-10-19
MX2018012392A (es) 2019-08-21
IL262191B2 (en) 2025-01-01
RU2747258C2 (ru) 2021-04-29
IL262191B1 (en) 2024-09-01
ZA201807187B (en) 2020-01-29
RU2018139523A (ru) 2020-05-15
US11278555B2 (en) 2022-03-22
US20190125769A1 (en) 2019-05-02
EP3442582A1 (en) 2019-02-20
SG11201808849TA (en) 2018-11-29
MX2022003190A (es) 2022-04-11
CN109862918A (zh) 2019-06-07
KR20190008206A (ko) 2019-01-23
BR112018070847A2 (pt) 2019-02-05
RU2021110230A (ru) 2021-05-26
MX390751B (es) 2025-03-21
JP2022031823A (ja) 2022-02-22
AU2017250732A1 (en) 2018-11-15
IL262191A (en) 2018-11-29
CN118304400A (zh) 2024-07-09
JP2019510807A (ja) 2019-04-18
KR20220139445A (ko) 2022-10-14
AU2023200591A1 (en) 2023-03-09
RU2018139523A3 (https=) 2020-07-07

Similar Documents

Publication Publication Date Title
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
Luo et al. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
US11013803B2 (en) Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer
EP2944323B1 (en) Agents for treating tumours, use and method thereof
Chiang et al. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
US20200377596A1 (en) Dosing of bispecific t cell engager
Donahue et al. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines
US20190328747A1 (en) Combinations including abx196 for the treatment of cancer
Lin et al. Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide–coated nanoparticles
Chen et al. Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
JP2023505303A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法
Lobo Immunological Effects of Photodynamic Therapy
Ma et al. Tandem high-dose chemotherapy without craniospinal irradiation in treatment of non-metastatic malignant brain tumors in very young children
Caccia Prolonged contact with dendritic cells turns lymph node‐resident NK cells into anti‐tumor effectors
Hickstein et al. Prolonged survival of renal allograft in rats by methotrexate-albumin conjugates as immunosuppressive therapy
Li et al. Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer
Berckmans et al. Inhibition of MDSC-induced immunosuppression in ovarian cancer through drug repurposing results in prolonged survival in ovarian cancer mice
US20230149547A1 (en) Reduced caloric intake and immunotherapy for the treatment of cancer
WO2023203561A1 (en) Apoptotic cell - check point inhibitor combination therapy
Ratain et al. 388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors
Wang et al. Reprogramming Chemoimmunotherapy via Biomimetic Cell Membrane-Clay Platform to Amplify Prime–Boost Antitumor Immunity
Hamri Targeting the microenvironment of 4T1 tumors using RGD-conjugated bacteriochlorophylls as a theranostic tool
Shapiro et al. First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)